Aids immunotherapy adsorber

Abstract

The invention relates to an aids immunotherapy adsorber, belonging to the field of medicine science. The aids immunotherapy adsorber is characterized in that HIV gp120 and gp41 antibodies are prepared by adopting genetic recombination and the hybridoma technology, anti-goat gp 120 and gp 41 antibodies are prepared by taking the prepared HIV gp120 and gp41 antibodies as antigens, agar gel is added according to a suitable ratio, a material with high biocompatibility is adopted for covering, so that the adsorber is prepared, the layering distribution with antibody titer from high to low and agar concentration from low to high is formed from an inlet to an outlet, the anti-goat gp 120 and gp 41 antibodies are completely combined, while HIV gp120 and gp 41 antibodies with high titer are left, in the extracorporeal circulation, when the separated plasma flows through the adsorber, the HIV forms the immobilized immune complex with the corresponding fixed antibody, and the immobilized immune complex is intercepted by the agar gel with high concentration and small micropores, and the plasma with HIV removed flows out from the adsorber, is mixed with hemocytes, and then is conveyed back to the body.

Description

technical field [0001] The invention relates to an adsorber for immunotherapy of AIDS in the medical field, which is mainly used for immune elimination of plasma HIV in the extracorporeal blood circulation of AIDS patients, so as to achieve the purpose of treating AIDS. Background technique [0002] AIDS is an infectious disease caused by human immunodeficiency virus (Human Immunodeficiency Virus, HIV). So far, 208 countries and regions in the world have been seriously threatened by AIDS. About 40 million people have been infected with AIDS, and the death toll has exceeded 20 million. About 6,000 people become AIDS-infected people every day, and more than 300 people die every day. on AIDS. HIV-infected people in China are in a period of rapid growth, and the number has far exceeded 1 million at present. AIDS has become another major infectious disease facing mankind after tumors, cardiovascular and cerebrovascular diseases, tuberculosis, and diabetes, and has become a seri...

AI Technical Summary

Problems solved by technology

However, the antibody cannot contact the virus remaining in the mononuclear macrophage, and the HIV envelope protein is prone to antigenic variation, and the original antibody loses its effect, so that the neutralizing antibody cannot play its due role

During the latent infection stage, the HIV provirus is integrated into the host cell genome, so HIV will not be recognized by the immune system, so it cannot be eliminated by autoimmunity alone

Another very important reason is that according to the mechanism of antibody killing and clearing antigens, after the immune antibody binds to the antigen, it must produce an immune effect, either by activating complement and mediating the ADCC effect to dissolve cellular antigens, but HIV is not a cellular antigen ; Either attract phagocytes to phagocytize and clear antigens through chemotaxis, but HIV is protected and proliferated in phagocytes instead; or antibodies combine with antigens to neutralize and lose infectivity, but HIV cannot be killed and cleared by the immune system

[0006] Judging from the current AIDS treatment methods that have been used clinically, the effect is not so ideal: (1) HIV reverse transcriptase inhibitors: can only prevent the infection of susceptible cells that have not been infected with HIV, and have no therapeutic effect on infected cells, and are toxic There are many side effects, including mitochondrial toxicity, myelosuppression, erythrocytic anemia, neutropenia and thrombocytopenia, pancreatitis, and the generation of cross-drug resistance. Drug-resistant variants, resulting in decreased clinical efficacy or failure

(2) HIV protease inhibitors: prone to drug-induced liver injury, lipid metabolism disorders and other side effects and drug resistance

(4) Inhibiting HIV virus entry inhibitors: including blocking the binding of gp120 to CD4, blocking the binding of HIV to coreceptors, acting on gp41 membrane subunits, and acting on CC chemokine receptor 5 (CCR5) on the surface of T lymphocytes to block HIV from entering host cells, but has side effects on the liver and heart

(6) HIV vaccine treatment: Due to the particularity of HIV, such as innate immunity is not enough to resist HIV and its targeted destruction of the immune system, and the virus mutates rapidly, so far no truly safe and effective vaccine has been developed

(7) Gene therapy: HIV gene therapy research has never stopped, including antisense technology, RNA decoy, RNA interference, intracellular antibodies, dominant negative mutants, suicide genes, etc., but gene therapy that has entered phase II clinical trials hardly

(8) Monoclonal antibody passive immunotherapy: reduce the susceptibility of HIV, delay the progression of AIDS and reduce the spread of HIV by down-regulating CCR5 on the surface of CD4+ T cells. Neutralizing monoclonal antibodies 2G12, 2F5 and 4E10 are applied to HIV-infected patients It has good tolerance and safety, and can delay but not prevent the rebound of the virus (9) Adoptive immune cell therapy: when a large number of HIV autologous CD4+ T cells are cultured in vitro, it will lead to a large amount of virus amplification and increase the CD4+ T cells infected by the virus. +T cell number, and reinfusion of CD4+T cells may increase the place where the virus replicates in the body, resulting in a rebound of the viral load. Generally speaking, adoptive immune cell therapy has no obvious side effects and has not achieved satisfactory therapeutic effect

Images